A new study found that more U.S. teenagers seeking treatment for cannabis use disorder faced delays in getting care, even as overall adolescent cannabis use leveled off or declined slightly over the past decade.
The study, published in the American Journal of Preventive Medicine, analyzed national data from more than 124,000 admissions of adolescents ages 12 to 17 to publicly funded substance use treatment facilities from 2012 to 2022.
Researchers found that about 34% of adolescents seeking treatment for cannabis use disorder in 2022 experienced an admission delay, defined as waiting several days to more than a month after an initial request for treatment. That was up from a low of about 25% in 2015.
Longer waits also became more common. The share of adolescents waiting a week or more peaked after the COVID-19 pandemic began, and about 5% waited at least 30 days to enter a treatment facility in 2022. The authors said elevated wait times from 2020 through 2022 may partly reflect pandemic-related disruptions and increased demand for care.
According to the study, about 11% of adolescents who use cannabis develop cannabis use disorder within a year, rising to about 20% with continued use. Other research cited in the study suggested about 4.7% of adolescents ages 12 to 17 met the diagnostic criteria for the disorder.
Adolescents referred to long-term rehabilitation or intensive outpatient programs had higher odds of delays than those entering acute detoxification services. Male adolescents had 11% higher odds of delay than female adolescents. Wait times also rose more sharply from 2018 to 2022 among adolescents ages 12 to 14 than among older teens.
The study found demographic differences as well. Non-Hispanic white adolescents had 29% higher odds of an admission delay than Hispanic adolescents, while Black, Asian, and American Indian or Alaska Native adolescents had lower odds than Hispanic peers.
The findings come as federal officials considered whether to reclassify marijuana under federal drug law. Moving marijuana from Schedule I to Schedule III would not immediately address local treatment capacity shortages.